Clarity Pharmaceuticals Ltd.

Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential

Novartis gets two androgen receptor protein degraders from Arvinas and Genentech-Adaptimmune terminate allogeneic T cell therapy deal

Plus: Acadia hires Elizabeth Thompson as head of R&D, and updates from Insitro, Fractyl, Adarx and more

Target, ligand and radioisotope choices fuel the growing field